NEW YORK (GenomeWeb) – Israeli biotech firm MeMed is embarking on a series of new clinical studies and platform development efforts as it aims to expand the reach of its ImmunoXpert test, a proteomic tool for guiding the use of antibiotics.
A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try 360Dx Premium now.
Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.